Chris Bosh Of Miami Heat Faces Another Blood Clot Scare As Xarelto Lawsuit Filings Increase

BloodThinnerHelp.com reports on a Business Insider article announcing that Miami Heat basketball star Chris Bosh is struggling with another potential blood clot scare. The article goes on to indicate that Bosh was likely going to spend his days following the injury reviewing options concerning his current basketball season and playing status. The article noted, “no determination will be made about his playing status until he goes through more tests and evaluation,” and that this information was provided by ‘a person with knowledge.’

Unfortunately, this is not Chris Bosh’s first blood clot scare. The player was the leading scorer for Miami, yet he has battled with regular health struggles. It was reported that Bosh was pulled from the All-Star Game and a 3-point contest because of what was first described as a ‘calf strain’. The article discusses an incident with Bosh from last season, stating the player, “...was shut down at the All-Star break...because a blood clot had found its way to one of his lungs, and that issue is something that Bosh believes started as a calf problem.”

Following the development of his first blood clot, Bosh teamed up with Xarelto manufacturer Janssen Pharmaceuticals (a subdivision of Johnson & Johnson corporation) to be a spokesperson. It was reported that during this time the athlete used the anticoagulant drug for several months. It is noted that it is extremely uncommon and also dangerous for players of various contact sports to be allowed to take blood thinners.

Xarelto is currently the subject of public controversy and more than 3,400 lawsuits which have been filed from across the United States and formed into two major groupings. Federally-filed Xarelto lawsuits have been transferred and consolidated to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation. They now form MDL number 2592 which includes more than 2,800 complaints. In addition, over 620 Xarelto lawsuits were consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania, forming a mass tort program there. Plaintiffs involved in all lawsuits share strikingly similar allegations concerning the drug’s link to an increased risk of sudden and dangerous bleeding events among patients using it, some of which have proven to be fatal.

As the involved plaintiffs await early 2017 bellwether trials, Attorney Joseph Osborne is working to help other patients who have taken Xarelto and who believe it has negatively impaired their health. He believes that these individuals are entitled to the important opportunity of evaluating their legal rights in the matter. Affected patients may be entitled to substantial compensation attained through legal action. Those who wish to look into their legal options further are currently offered free legal consultations by Attorney Osborne.

To request more information concerning Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.